Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ADHD attention turns to drugs that are easier to swallow

This article was originally published in Scrip

Executive Summary

With both generic and newer drugs prevalent on the attention deficit hyperactivity disorder (ADHD) market, some of the focus has shifted to newer products catering to patients experiencing difficulties swallowing pills. The latest to embark into this space is Neos Therapeutics, which said the US FDA has accepted for review its NDA for NT0202 an extended release orally disintegrating tablet (ODT) formulation of amphetamine polistirex for the treatment of ADHD.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts